文献速递乳腺癌

21基因检测复发评分与淋巴结阳性乳腺癌局部区域复发率的关联

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
PubMed 文献 · JAMA Oncol · 2020-01-01

该研究基于S8814随机试验的回顾性队列,分析绝经后激素受体阳性、淋巴结阳性乳腺癌患者中21基因复发评分与局部区域复发(LRR)的关系。提示复发评分可能辅助放疗决策。

核心结论

  • 调整治疗、手术方式和阳性淋巴结数后,较高复发评分与增加的局部区域复发风险相关。
  • 复发评分或可与临床变量联合用于放疗决策时评估LRR风险。

研究设计与样本

  • 回顾性队列分析,基于SWOG S8814三期随机临床试验。
  • 纳入绝经后ER/PR阳性、淋巴结阳性乳腺癌患者,接受他莫昔芬单药、化疗后他莫昔芬或同期他莫昔芬加化疗。
  • 北美临床中心于1989年6月至1995年7月入组,最终分析316例,中位随访8.7年(IQR 7.0-10.2)。

主要发现

  • 低评分组121例中7例(5.8%)发生LRR,中高评分组195例中27例(13.8%)发生LRR。

临床怎么用

  • 对于绝经后激素受体阳性、淋巴结阳性乳腺癌患者,复发评分可能辅助评估局部区域复发风险。
  • 在考虑放疗决策时,可将复发评分与常规临床变量结合使用。

局限性

  • 回顾性分析,样本量有限(316例),LRR事件数较少。
  • 未报告放疗对LRR影响的随机比较,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The 21-gene assay recurrence score is increasingly used to personalize treatment recommendations for systemic therapy in postmenopausal women with estrogen receptor (ER)- or progesterone receptor (PR)-positive, node-positive breast cancer; however, the relevance of the 21-gene assay to radiotherapy decisions remains uncertain. OBJECTIVE: To examine the association between recurrence score and locoregional recurrence (LRR) in a postmenopausal patient population treated with adjuvant chemotherapy followed by tamoxifen or tamoxifen alone. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a retrospective analysis of the Southwest Oncology Group S8814, a phase 3 randomized clinical trial of postmenopausal women with ER/PR-positive, node-positive breast cancer treated with tamoxifen alone, chemotherapy followed by tamoxifen, or concurrent tamoxifen and chemotherapy. Patients at North American clinical centers were enrolled from June 1989 to July 1995. Medical records from patients with recurrence score information were reviewed for LRR and radiotherapy use. Primary analysis included 316 patients and excluded 37 who received both mastectomy and radiotherapy, 9 who received breast-conserving surgery without documented radiotherapy, and 5 with unknown surgical type. All analyses were performed from January 22, 2016, to August 9, 2019. MAIN OUTCOMES AND MEASURES: The LRR was defined as a recurrence in the breast; chest wall; or axillary, infraclavicular, supraclavicular, or internal mammary lymph nodes. Time to LRR was tested with log-rank tests and Cox proportional hazards regression for multivariate models. RESULTS: The final cohort of this study comprised 316 women with a mean (range) age of 60.4 (44-81) years. Median (interquartile range) follow-up for those without LRR was 8.7 (7.0-10.2) years. Seven LRR events (5.8%) among 121 patients with low recurrence score and 27 LRR events (13.8%) among 195 patients with intermediate or high recurrence score occurred. The estimated 10-year cumulative incidence rates were 9.7% for those with a low recurrence score and 16.5% for the group with intermediate or high recurrence score (P = .02). Among patients who had a mastectomy without radiotherapy (n = 252), the differences in the 10-year actuarial LRR rates remained significant: 7.7 % for the low recurrence score group vs 16.8% for the intermediate or high recurrence score group (P = .03). A multivariable model controlling for randomized treatment, number of positive nodes, and surgical type showed that a higher recurrence score was prognostic for LRR (hazard ratio [HR], 2.36; 95% CI, 1.02-5.45; P = .04). In a subset analysis of patients with a mastectomy and 1 to 3 involved nodes who did not receive radiation therapy, the group with a low recurrence score had a 1.5% rate of LRR, whereas the group with an intermediate or high recurrence score had a 11.1% LRR (P = .051). CONCLUSIONS AND RELEVANCE: This study found that higher recurrence scores were associated with increased LRR after adjustment for treatment, type of surgical procedure, and number of positive nodes. This finding suggests that the recurrence score may be used, along with accepted clinical variables, to assess the risk of LRR during radiotherapy decision-making.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Woodward WA, Barlow WE, Jagsi R, et al. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. JAMA Oncol. 2020. PMID: 31917424. doi:10.1001/jamaoncol.2019.5559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。